News stories about Transgenomic (NASDAQ:PRPO) have trended somewhat positive on Wednesday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Transgenomic earned a media sentiment score of 0.00 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.2743120269713 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Separately, ValuEngine lowered shares of Transgenomic from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.
Shares of Transgenomic (NASDAQ:PRPO) opened at $1.37 on Wednesday. Transgenomic has a twelve month low of $1.22 and a twelve month high of $47.70. The company has a quick ratio of 0.10, a current ratio of 0.11 and a debt-to-equity ratio of 0.01.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/11/15/transgenomic-prpo-earning-somewhat-favorable-news-coverage-report-finds.html.
Precipio, Inc, formerly Transgenomic, Inc, is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment.
Receive News & Ratings for Transgenomic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgenomic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.